BRAF and thyroid gland carcinoma: Using AF of BRAF V600E mutation > 28.2% to predict the recurrence of intermediate and high risk PTC has a sensitivity of 60% and a specificity of 80%, making it a potential new indicator for predicting the risk of thyroid cancer recurrence.